• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中药治疗糖耐量受损的系统评价和 Meta 分析: 随机对照试验。

Traditional Chinese Patent Medicine for Treating Impaired Glucose Tolerance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

机构信息

1 Department of Endocrinology, Guang'anmen Hospital of China Academy of Chinese Medical Sciences , Beijing, China .

2 South Area of Guang'anmen Hospital of China Academy of Chinese Medical Sciences , Beijing, China .

出版信息

J Altern Complement Med. 2018 Jul;24(7):634-655. doi: 10.1089/acm.2017.0302. Epub 2018 Apr 6.

DOI:10.1089/acm.2017.0302
PMID:29624416
Abstract

INTRODUCTION/AIM: To assess the effectiveness and safety of Traditional Chinese patent medicines (TCPMs) for managing impaired glucose tolerance (IGT).

METHODS

Seven databases were searched to identify eligible trials published from incepting to May 1, 2016. Randomized controlled trials (RCTs) involving TCPM for IGT with a minimum follow-up duration of 6 months were included for analysis. Data extraction and quality assessment were performed by two reviewers independently. Data synthesis was analyzed using Review Manager 5.3 software. Subgroup analysis was carried out to assess the robustness of results of meta-analysis.

RESULTS

Eighteen trials with a total of 3172 participants met the inclusion criteria. The methodological quality of the RCTs was variable. Comparing with receiving lifestyle modification (LM) alone, TCPM plus LM was significantly better at reducing the incidence of diabetes (risk ratio [RR] 0.45; 95% confidence interval [CI] 0.36-0.57, p < 0.00001) and normalizing the blood glucose (RR 0.72; 95% CI 0.64-0.82, p < 0.00001). TCPM plus LM was superior in decreasing the levels of 2hPG, body mass index (BMI), fasting insulin, and 2 h insulin compared with LM alone (2hPG: mean difference [MD] -1.13; 95% CI -1.68 to -0.58, p < 0.0001; BMI: MD -0.42; 95% CI -0.71 to -0.14, p = 0.004; fasting insulin: MD -2.44; 95% CI -3.79 to -1.09, p = 0.0004; and 2 h insulin: MD -8.26; 95% CI -8.47 to -8.05, p < 0.00001). Compared with placebo plus LM, TCPM plus LM was superior in reducing diabetes (RR 0.54; 95% CI 0.42-0.69, p < 0.00001) and normalizing blood glucose (RR 0.55; 95% CI 0.41-0.73, p < 0.00001; the interventions were also associated with a decline in the two-hour postprandial blood glucose (2hPG) levels (MD -1.45; 95% CI -2.11 to -0.79, p < 0.0001) and BMI levels (MD -1.12; 95% CI -2.00 to -0.24, p < 0.0001). There were no significant differences in adverse events between two groups. Subgroup analysis found no significant difference in overall effects among all study characteristics, indicating that the overall effects were stable.

CONCLUSIONS

The study indicated that TCPM combined with moderate lifestyle modification had significant effect on IGT. Further studies are needed to provide more reliable evidence. The PROSPERO registration is No. CRD42016039312.

摘要

介绍/目的:评估中药复方治疗糖耐量受损(IGT)的有效性和安全性。

方法

检索了七个数据库,以确定从成立到 2016 年 5 月 1 日发表的合格试验。纳入了至少随访 6 个月的 TCPM 治疗 IGT 的随机对照试验(RCT)进行分析。两名评审员独立进行数据提取和质量评估。使用 Review Manager 5.3 软件进行数据分析。进行亚组分析以评估荟萃分析结果的稳健性。

结果

共有 18 项试验,共 3172 名参与者符合纳入标准。RCT 的方法学质量各不相同。与单独接受生活方式改变(LM)相比,中药复方加 LM 显著降低糖尿病发病率(风险比 [RR] 0.45;95%置信区间 [CI] 0.36-0.57,p<0.00001)和血糖正常化(RR 0.72;95% CI 0.64-0.82,p<0.00001)。与单独接受 LM 相比,中药复方加 LM 可降低 2hPG、体重指数(BMI)、空腹胰岛素和 2 小时胰岛素水平(2hPG:MD-1.13;95%CI-1.68 至-0.58,p<0.0001;BMI:MD-0.42;95%CI-0.71 至-0.14,p=0.004;空腹胰岛素:MD-2.44;95%CI-3.79 至-1.09,p=0.0004;和 2 小时胰岛素:MD-8.26;95%CI-8.47 至-8.05,p<0.00001)。与安慰剂加 LM 相比,中药复方加 LM 可降低糖尿病(RR 0.54;95%CI 0.42-0.69,p<0.00001)和血糖正常化(RR 0.55;95%CI 0.41-0.73,p<0.00001;干预措施还与餐后两小时血糖(2hPG)水平(MD-1.45;95%CI-2.11 至-0.79,p<0.0001)和 BMI 水平(MD-1.12;95%CI-2.00 至-0.24,p<0.0001)的下降相关。两组间不良反应无显著差异。亚组分析发现,所有研究特征的总体效果差异无统计学意义,表明总体效果稳定。

结论

该研究表明,中药复方联合中等强度生活方式改变对 IGT 有显著疗效。需要进一步研究提供更可靠的证据。PROSPERO 注册号为 No. CRD42016039312。

相似文献

1
Traditional Chinese Patent Medicine for Treating Impaired Glucose Tolerance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.中药治疗糖耐量受损的系统评价和 Meta 分析: 随机对照试验。
J Altern Complement Med. 2018 Jul;24(7):634-655. doi: 10.1089/acm.2017.0302. Epub 2018 Apr 6.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
4
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.孕期超重或肥胖女性使用二甲双胍以改善母婴结局。
Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD010564. doi: 10.1002/14651858.CD010564.pub2.
5
Surgical approaches for inserting hemiarthroplasty of the hip in people with hip fractures.髋部骨折患者行半髋关节置换术的手术入路
Cochrane Database Syst Rev. 2025 Jun 13;6(6):CD016031. doi: 10.1002/14651858.CD016031.
6
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.放疗或放射外科手术后脑放射性坏死的治疗干预措施。
Cochrane Database Syst Rev. 2018 Jul 9;7(7):CD011492. doi: 10.1002/14651858.CD011492.pub2.
7
Heliox for croup in children.氦氧混合气治疗儿童喉炎。
Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD006822. doi: 10.1002/14651858.CD006822.pub6.
8
Negative pressure wound therapy for open traumatic wounds.开放性创伤伤口的负压伤口治疗
Cochrane Database Syst Rev. 2018 Jul 3;7(7):CD012522. doi: 10.1002/14651858.CD012522.pub2.
9
Psychological therapies for treatment-resistant depression in adults.成人难治性抑郁症的心理治疗
Cochrane Database Syst Rev. 2018 May 14;5(5):CD010558. doi: 10.1002/14651858.CD010558.pub2.
10
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD010216. doi: 10.1002/14651858.CD010216.pub7.

引用本文的文献

1
Efficacy of Xiaokeqing granules and lifestyle intervention in treating prediabetes mellitus considering metabolomic biomarkers: A randomised controlled trial.基于代谢组学生物标志物探讨消渴清颗粒联合生活方式干预治疗糖尿病前期的疗效:一项随机对照试验
World J Diabetes. 2025 Jul 15;16(7):105219. doi: 10.4239/wjd.v16.i7.105219.
2
Dilemmas in Elderly Diabetes and Clinical Practice Involving Traditional Chinese Medicine.老年糖尿病的困境与涉及中医药的临床实践
Pharmaceuticals (Basel). 2024 Jul 16;17(7):953. doi: 10.3390/ph17070953.
3
Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis.
糖尿病前期患者血脂异常的中成药治疗选择:一项系统评价与网状Meta分析
Front Pharmacol. 2022 Aug 29;13:942563. doi: 10.3389/fphar.2022.942563. eCollection 2022.
4
Prevention of Diabetes in Overweight/Obese Adults through Traditional Chinese Patent Medicine: Study Protocol for a Prospective Cohort Study.通过中成药预防超重/肥胖成年人糖尿病:一项前瞻性队列研究的研究方案
Evid Based Complement Alternat Med. 2021 Nov 8;2021:6006802. doi: 10.1155/2021/6006802. eCollection 2021.
5
Dietary supplements for prediabetes: A protocol for a systematic review and meta-analysis.糖尿病前期的膳食补充剂:一项系统评价与荟萃分析方案
Medicine (Baltimore). 2020 May;99(20):e20347. doi: 10.1097/MD.0000000000020347.